Modulation of interleukin 17b and 25 activity associated with melatonin as inductor of apoptosis in cell culture of mammary neoplasms

• Grant number: 12/25191-0
• Support Opportunities: Scholarships abroad - Research Internship - Doctorate
• Start date: March 16, 2013
• End date: August 15, 2013
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Animal Pathology
• Principal Investigator: Debora Aparecida Pires de Campos Zuccari
• Grantee: Gabriela Bottaro Gelaleti
• Supervisor: Alicia Mercedes Viloria-Petit
• Host Institution: Instituto de Biociências, Letras e Ciências Exatas (IBILCE). Universidade Estadual Paulista (UNESP). Campus de São José do Rio Preto. São José do Rio Preto , SP, Brazil
• Institution abroad: University of Guelph, Canada
• Associated to the scholarship: 12/02128-1 - Modulation of Interleukin 17B and 25 Activity Associated with Melatonin as Inductor of Apoptosis in Cell Culture of Mammary Neoplasms, BP.DR

Abstract

Cytokines are intercellular mediators that regulate survival, differentiation and effector functions of cells and has been proven its relationship to cancer. Some of them have already defined activity, but the understanding of its interaction with the genesis and tumor progression may contribute to the success of therapeutic and preventive protocols. The IL-25 is known for its role in the immune response and it is known that the interaction with its receptor IL-25R induces cell apoptosis. Little is known about this interaction, only that there is competition for the site of action with IL-17B in neoplastic cells, contributing to tumor progression of these cells. It has been suggested that melatonin may protect normal cells from apoptosis and conversely induce it on tumor cells. The objective of this study is to control tumor growth through increased apoptosis as a therapeutic strategy in mammary neoplasms. The canine tumor cell lines CMT-U229 and P114 cell line and normal epithelial canine CF-41 will be grown in three-dimensional growth for itself and after its establishment will be treated with IL-25 with or without melatonin. Will be checked cell proliferation and apoptosis by MTT assay, immunofluorescence assay, western blotting and real-time PCR. The results will enable the use of interleukins associated or not with melatonin as therapeutic agents in breast cancer. (AU)